Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.1.301

Clinical Application of Serum Tumor Associated Material (TAM) from Non-small Cell Lung Cancer Patients  

Li, Cheng-Guang (Department of Chemotherapy, The Affiliated JiangSu Cancer Hospital of Nanjing Medical University)
Huang, Xin-En (Department of Chemotherapy, The Affiliated JiangSu Cancer Hospital of Nanjing Medical University)
Xu, Lin (Department of Thoracic Surgery, The Affiliated JiangSu Cancer Hospital of Nanjing Medical University)
Li, Ying (Department of Chemotherapy, The Affiliated JiangSu Cancer Hospital of Nanjing Medical University)
Lu, Yan-Yan (Department of Chemotherapy, The Affiliated JiangSu Cancer Hospital of Nanjing Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.1, 2012 , pp. 301-304 More about this Journal
Abstract
Objective: To explore the associations of serum tumor associated material (TAM) with other common tumor markers like carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), carbohydrate antigen19-9 (CA19-9) and its clinical application in non-small cell lung cancer (NSCLC) patients. Methods: A total of 87 patients were enrolled into this study, all with histologically or cytologically confirmed NSCLC. With the method of chemical colorimetry, the level of TAM was determined and compared, while chemiluminescence was used to measure the levels of common tumor markers. Results: The level of TAM decreased after chemotherapy compared with before chemotherapy when CT or MRI scans showed disease control. Furthermore, it increased when disease progessed and there was no statistically significant difference in monitoring of TAM and common tumor markers (P>0.05). Conclusions: Detecting TAM in NSCLC patients has a higher sensitivity and specificity, so it can be used as an indicator for clinical monitoring of lung cancer chemotherapy.
Keywords
Tumor associated material; tumor marker; lung cancer; NSCLC;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Wu HX, et al (1983). Encyclopedia of Chinese Medical Oncology. Shanghai Science and Technology Press, 63 (Chinese).
2 Yan PW, Huang XE, Jiang Y, et al (2010). A clinical comparison on safety and efficacy of Paclitaxel/Epirubicin (NE) with Fluorouracil/Epirubicin/Cyclophosphamide (FEC) as postoperative adjuvant chemotherapy in breast cancer. Asian Pac J Cancer Prev, 11, 1115-8.
3 Zhang S, Cordon-Cardo C, Zhang HS, et al (1997). Selection of tumor antigens as targets for immune attack using immunohistochemistry: I.Focus on gangliosides. Int J Cancer, 73, 42-9.   DOI
4 Zhang S, Zhang HS, Cordon-Cardo C, et al (1997). Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. Int J Cancer, 73, 50-6.   DOI
5 Zhou JN, Huang XE, Ye Z, et al (2009). Weekly paclitaxel/ Docetaxel combined with a paltinum in the treatment of advanced non-samll cell lung cancer: a study on efficacy, safety and pre-medication. Asian Pac J Cancer Prev, 10, 1147-50.
6 Zou X, Zhang XS, Sui L, et al (2004). Role of tulnor associated material (BXTM) in early diagnosing malignant tumor. Qilu J Med Laboratory Sci, 15, 4-6.
7 Meezan E, Wu HC, Black PH, et al (1969). Comparative studies on carbohydrate-containing membrane components of normal and virus-transformed mouse fibroblasts. Separation of glycoproteins and glycopeptides by sephadex chromatography. Biochemistry, 8, 2518-24.   DOI
8 Peracaula R, Tabarés G, Royle L, et al (2003). Altered glycosylation pattern allows the distinction between prostatespecifc antigen (PSA) from normal and tumor origins. Glycobiology, 13, 457-70.   DOI
9 Orntoft TF, Vestergaard EM (1999). Clinical aspects of altered glycosylation of glycoproteins in cancer. Electrophoresis, 20, 362-71.   DOI
10 Pancino G, Osinaga E, Charpin C, et al (1991). Purification and characterization of a breast-cancer-associated glycoprotein not expressed in normal breast and identified by monoclonal antibody 83D4. Brit J Cancer, 63, 390-8.   DOI
11 Saussez S, Marchant H, Nagy N, et al (1998). Quantitative glycohistochemistry defines new prognostic markers for cancers of the oral cavity. Cancer, 82, 252-60.   DOI
12 Sell S (1990). Cancer-associated carbohydrates identified by monoclonal antibodies. Human Path, 21, 1003-19.   DOI
13 Serum tumor associated material (TAM) testing kit, QINGDAO BO-XING Biotechnology Co., Ltd. http://www.cqtrueway.com.
14 Shriver Z, Raguram S, Sasisekharan R (2004). Glycomics: a pathway to a class of new and improved therapeutics. Nat Rev Drug Disc, 3, 863-73.   DOI
15 Taylor-Papadimitriou J, Epenetos AA (1994). Exploiting altered glycosylation patterns in cancer- progress and challenges in diagnosis and therapy. Trends Biotech, 12, 227-33.   DOI
16 Turner GA (1992). N-Glycosylation of serum-proteins in disease and its investigation using lectins. Clin Chim Acta, 208, 149-71.   DOI
17 Vinolas N, GalanMC, Casas F, et al (1998). Tumor markers inresponse monitoring and prognosis of non small cell lungcancer. Preliminaryreport Anticancer Res, 18, 631-4.
18 Hakomori S (2000). Traveling for the glycosphingolipid path. Glycoconj J, 17, 627-47.   DOI
19 Gabius HJ (1988). Tumor lectinology- at the intersection of carbohydrate chemistry, biochemistry, cell biology, and oncology. Angew Chem, 27, 1267-76.   DOI
20 Gehan EA, Tefft MC (2000). Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)? J Natl Cancer Inst, 92, 179-81.   DOI
21 Hakomori S, Zhang Y (1997). Glycosphingolipid antigens and cancer therapy. Chem Biol, 4, 97-104.   DOI
22 Hollingsworth MA, Swanson BJ (2004). Mucins in cancer: Protection and control of the cell surface. Nat Rev Cancer, 4, 45-60.   DOI
23 Jiang M, Pu R (2010). Study on serum tumor related material (BXTM) with early diagnosis in malignant tumor. National Medical Frontiers of China, 5, 80-1.
24 Kim YJ, Varki A (1997). Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj J, 14, 569-76.   DOI
25 Kui Wong N, Easton RL, Panico M, et al (2003). Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. J Biol Chem, 278, 28619-34.   DOI
26 Liu ZM, et al (1986). Serum free proline and free hydroxyproline and its peptide-binding determination of hydroxyproline in the evaluation of bone tumors. Chinese J Laboratory Med, 9, 129-33 (Chinese).
27 MacDonald JS (1999). Carcinoembryonic antigen screening: Pros and cons. Sem Oncol, 26, 556-60.
28 Matsushita Y, Cleary KR, Ota DM, et al(1990).Sialyl-dimeric Lewis-X antigen expressed on mucin-like glycoproteins in colorectal-cancer metastases. Lab Invest,63, 780-91.
29 Dennis JW, Laferte S, Waghorne C, et al (1987). $\beta$1-6 branching of asn-linked oligosaccharides is directly associated with metastasis. Science, 236, 582-5.   DOI
30 Basu PS, Majhi R, Batabyal SK (2003). Lectin and serum-PSA interaction as a screeninng test for prostate cancer. Clin Biochem, 36, 373-6.   DOI
31 Deng H, Zhong BY, Peng GH, et al (2010). Application of Bo Xin SerumTumor Associated Material ( BXTM) in Malignant Tumor. Prac Prev Med, 17, 2493-5.
32 Diez M, Torres A, Maestro ML, et al (1996). Prediction of survival and recurrence by serum and cytosolic level sof CEA, CA125 and SCC antigens in resectable non-small-cell lung cancer. Br J Cancer, 73, 1248-54.   DOI
33 Foa P, Fornier M, Miceli R, et al (1999). Tumour markers CEA, NSE, SCC, TPA and CYFRA21.1 in resectable non-small cell lungcancer. Anticancer Res, 19, 3613-8.